| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| Targets |
Polyinosinic acid sodium targets Toll-like Receptor 3 (TLR3), a pattern recognition receptor that recognizes double-stranded RNA and plays a critical role in antiviral immunity. As a TLR3 ligand, it activates the innate immune system through the TRIF-dependent signaling pathway. This activation leads to the production of pro-inflammatory cytokines and type I interferons, enhancing cellular immune responses.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that Polyinosinic acid sodium is a TLR3 ligand that enhances cellular immune responses through TLR3 and TRIF. As a single-stranded homonucleic acid, it activates the innate immune system. The compound has potential applications in immune regulation. Detailed in vitro activity data, including specific EC50 values and cytokine induction profiles, are not extensively documented in the available literature.
|
| ln Vivo |
In vivo activity of Polyinosinic acid sodium is related to its function as a TLR3 agonist that modulates immune responses through activation of the innate immune system. By engaging TLR3 and TRIF, the compound enhances cellular immune responses. It has potential applications in immune regulation. Detailed in vivo efficacy data from animal models, including antiviral and immunomodulatory studies, are not extensively documented in the available literature.
|
| Enzyme Assay |
The in vitro receptor binding assay for Polyinosinic acid sodium involves measuring its agonistic activity at Toll-like Receptor 3 (TLR3). Cell-based reporter assays using HEK293 cells expressing human TLR3 and an NF-κB-driven luciferase reporter are commonly employed. Cells are treated with varying concentrations of Polyinosinic acid sodium, and TLR3 activation is measured by luciferase activity. Cytokine production (IFN-β, IL-6, TNF-α) is measured by ELISA in immune cell cultures. Standard protocols include appropriate controls such as poly(I:C) positive controls.
|
| Cell Assay |
In vitro cell-based assays for Polyinosinic acid sodium are conducted using immune cell lines such as dendritic cells, macrophages, or epithelial cells expressing TLR3. Cells are treated with the compound at various concentrations, and TLR3 activation is assessed by measuring cytokine production (IFN-β, IL-6, TNF-α) using ELISA or qPCR. Cell surface marker expression is evaluated by flow cytometry to assess immune cell activation. Standard protocols include appropriate positive controls such as poly(I:C) and vehicle controls.
|
| Animal Protocol |
In vivo animal studies for Polyinosinic acid sodium are typically conducted using mouse models to evaluate TLR3-mediated immune activation and antiviral responses. Animals are administered the compound via intraperitoneal or intravenous routes at various doses. Immune responses are assessed by measuring serum cytokine levels and evaluating immune cell activation. The compound's potential in immune regulation and antiviral therapy is investigated. Standard protocols include appropriate controls such as vehicle-treated groups and known TLR3 agonists.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Polyinosinic acid sodium include its solubility in H2O at 100 mg/mL with ultrasonic assistance. The compound has a formula of (C10H13N4O8P)x.xNa. Storage recommendations include 4°C, sealed storage away from moisture and light. As a nucleic acid-based compound, it is subject to degradation by nucleases in biological fluids. Detailed pharmacokinetic parameters such as half-life and bioavailability are not extensively documented. The compound is intended for research use only.
|
| Toxicity/Toxicokinetics |
Toxicity information for Polyinosinic acid sodium is limited in the available literature. As a TLR3 agonist, it may induce inflammatory responses that could lead to dose-dependent toxicity. Standard safety precautions for handling research chemicals should be followed. The compound is designated for research use only and is not for human therapeutic applications. No detailed acute or chronic toxicity data are available from the search results.
|
| References | |
| Additional Infomation |
Polyinosinic acid sodium is the sodium form of Polyinosinic acid, a single-stranded homonucleic acid that acts as a TLR3 ligand. By engaging TLR3 and TRIF, it enhances cellular immune responses. It has potential applications in immune regulation. It has CAS 33378-44-8. It is soluble in H2O at 100 mg/mL. It is intended for research use only.
|
| Molecular Formula |
C10H13N4O8P
|
|---|---|
| Exact Mass |
403.099
|
| CAS # |
33378-44-8
|
| PubChem CID |
177671740
|
| Appearance |
Solid powder
|
| Hydrogen Bond Donor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
26
|
| Complexity |
555
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C.C.C1=NC2=C(C(=O)N1)N=CN2[C@H]3[C@H](C([C@H](O3)COP(=O)(O)O)O)O.[Na]
|
| InChi Key |
UVNAEDPNYHQLAL-BCYSCTGWSA-N
|
| InChi Code |
InChI=1S/C10H13N4O8P.2CH4.Na/c15-6-4(1-21-23(18,19)20)22-10(7(6)16)14-3-13-5-8(14)11-2-12-9(5)17;;;/h2-4,6-7,10,15-16H,1H2,(H,11,12,17)(H2,18,19,20);2*1H4;/t4-,6?,7+,10-;;;/m1.../s1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~100 mg/mL (with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
